貴州百靈(002424.SZ):參股子公司賾靈生物引入7家投資方 投後估值7億元
格隆匯12月7日丨貴州百靈(002424.SZ)公佈,公司參股子公司成都賾靈生物醫藥科技有限公司(簡稱“成都賾靈”)擬增資4974.01萬元。新增註冊資本中的1150萬元用於員工股權激勵,由原股東成都眾信匯智企業管理合夥企業(有限合夥)認繳;新增註冊資本3824.01萬元由投資方認繳。7家投資方向成都賾靈投資9500萬元,其中以3824.01萬元認購成都賾靈新增註冊資本3824.01萬元,剩餘5675.99萬元計入成都賾靈資本公積金。近日,成都賾靈的原股東及各投資方簽訂了《增資協議》。成都賾靈完成該次增資後估值將由投前的6億元增長至7億元。
成都賾靈是四川大學華西醫院陳俐娟教授、貴州百靈企業集團製藥股份有限公司、四川大學華西醫院全資子公司華西健康科技有限公司於2019年順應《藥品管理法》和四川大學華西醫院成果轉化“華西九條”成立的專業從事新藥研發的創新型企業。成都賾靈現共佈局在研創新藥產品管線9個(確定+備選),涉及惡性腫瘤、自身免疫性疾病、神經系統疾病、消化系統疾病等多個管線,涵蓋小分子藥物、ADC(抗體偶聯藥物)等。
公司表示,通過該次增資,成都賾靈將進一步優化股東結構,為今後繼續社會化發展方向奠定了基礎。同時成都賾靈的在研項目也得到了廣大投資人和社會的認可,僅用兩年時間成都賾靈由初創時註冊資本6667萬元已發展到估值7億元。公司作為創始股東和戰略投資人也將持續關注成都賾靈的未來發展,為成都賾靈穩健開展資本化運作提供幫助,增強其核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.